Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

被引：9
|
作者：
Llombart-Cussac, Antonio
Sledge, George
Toi, Masakazu
Neven, Patrick
Sohn, Joo Hyuk
Inoue, Kenichi
Pivot, Xavier
Okera, Meena
Masuda, Norikazu
Kaufman, Peter A.
Koh, Han
Grischke, Eva-Maria
Conte, PierFranco
Andre, Valerie
Bian, Yuanyuan
Shahir, Ashwin
van Hal, Gertjan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD13-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD13-11
引用
收藏
页数：3
相关论文
共 50 条
  • [41] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [42] Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study
    Jiang, Zefei
    Hu, Xichun
    Zhang, Qingyuan
    Sun, Tao
    Yin, Yongmei
    Li, Huiping
    Yan, Min
    Tong, Zhongsheng
    Oppermann, Christina Pimentel
    Liu, Yunpeng
    Costa, Romulo
    Li, Man
    Chen, Xi
    Cheng, Ying
    Ouyang, Quchang
    Liao, Ning
    Wang, Xiaojia
    Wu, Xinhong
    Feng, Jifeng
    Hegg, Roberto
    Setty, Govindbabu Kanaka
    Agarwal, Amit
    Bajpai, Jyoti
    Cheng, Jing
    Girotto, Gustavo
    Goswami, Chanchal
    Hu, Wenjing
    Huang, Jian
    Portugal, M. A. Coccia
    Yang, Jin
    Zheng, Rongsheng
    Franke, Fabio Andre
    Liu, Qiang
    Liu, Yunjiang
    Lu, Yongkui
    Souza, Cristiano
    Yu, Shiying
    Kilara, Nalini
    Panchal, Harsha
    Singh, Ashish
    Nag, Shona
    Liu, Jian
    Rapoport, Bernardo
    Tabane, Neonyana Keorapetse Rebecca
    Wang, Hongxia
    Wang, Ning
    Han, Rubing
    Zhang, Wanli
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Gilchrist, Jenny
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [44] Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib.
    Tamragouri, Keerthi
    Cobleigh, Melody A.
    Rao, Ruta D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [46] Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis
    Taniguchi, Azusa
    Kittaka, Nobutohi
    Kanaoka, Haruka
    Nakajima, Satomi
    Oyama, Yuri
    Seto, Yukiko
    Soma, Ai
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nishio, Minako
    Fujisawa, Fumie
    Nakayama, Takahiro
    ANTICANCER RESEARCH, 2022, 42 (12) : 6027 - 6035
  • [47] Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
    Rugo, Hope S.
    Haltner, Anja
    Zhan, Lin
    Tran, Anh
    Bananis, Eustratios
    Hooper, Becky
    Mitra, Debanjali
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 457 - 467
  • [48] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [49] Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
    Battisti, Nicolo Matteo Luca
    Morrison, Laura
    Nash, Tamsin
    Senthivel, Nishanti
    Kestenbaum, Samantha
    Begum, Parvin
    Obeid, Mariam
    Hayhurst, William
    Yang, Dorothy
    Gafoor, Shafiah
    Brown, Caroline
    Rehman, Farah
    Kenny, Laura
    Hatcher, Olivia
    Susan, Susan
    Williams, Jennet
    Brown, Anna
    Rozati, Hamoun
    Alexandros, Alexandros
    Sawyer, Elinor
    Gousis, Charalampos
    Karapanagiotou, Eleni
    Rigg, Anna
    Rapti, Kleopatra
    Roylance, Rebecca
    Beresford, Mark
    Gee, Abigail L.
    Konstantis, Apostolos
    King, Judy
    Nathan, Mark
    Spurrell, Emma
    Pearce, Mark
    Bradwell, Dane
    Denton, Arshi
    Swain, Kate
    McGrath, Sophie
    Allen, Mark
    Ring, Alistair
    Johnston, Stephen
    Raja, Fharat
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
    Malorni, Luca
    Tyekucheva, Svitlana'
    Hilbers, Florentine S.
    Ignatiadis, Michail
    Neven, Patrick
    Colleoni, Marco
    Henry, Stephanie
    Ballestrero, Alberto
    Bonetti, Andrea
    Jerusalem, Guy
    Papadimitriou, Konstantinos
    Bernardo, Antonio
    Seles, Elena
    Duhoux, Francois P.
    MacPherson, Iain R.
    Thomson, Alastair
    Davies, David Mark
    Bergqvist, Mattias
    Migliaccio, Ilenia
    Gebhart, Geraldine
    Zoppoli, Gabriele
    Bliss, Judith M.
    Benelli, Matteo
    McCartney, Amelia
    Kammler, Roswitha
    De Swert, Heidi
    Ruepp, Barbara
    Fumagalli, Debora
    Maibach, Rudolf
    Cameron, David
    Loi, Sherene
    Piccart, Martine
    Regan, Meredith M.
    EUROPEAN JOURNAL OF CANCER, 2022, 164 : 39 - 51
12345